- Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma
-
Na JC, Kim JH, Kim SY, Gu YR, Jun DY, Lee HH, Yoon YE, Choi KH, Hong SJ, Han WK
- KMID: 2471078
- Investig Clin Urol.
- 2020 Mar;61(2):216-223.
- doi: 10.4111/icu.2020.61.2.216
PURPOSE: Renal cell carcinoma is a heterogeneous kidney cancer, and over 403,000 cases were reported worldwide in 2018. Current methods for studying renal cell carcinoma are limited to two-dimensional (2D)... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study
-
Kim SH, Lee DE, Joung JY, Seo HK, Lee KH, Chung J
- KMID: 2471070
- Investig Clin Urol.
- 2020 Mar;61(2):146-157.
- doi: 10.4111/icu.2020.61.2.146
PURPOSE: This study aimed to compare progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) in Heng intermediate-risk patients with metastatic renal cell carcinoma (mRCC) treated with first-line immunotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of perioperative blood transfusion on oncologic outcomes in patients with nonmetastatic renal cell carcinoma treated with curative nephrectomy: A retrospective analysis of a large, single-institutional cohort
-
Seon DY, Kwak C, Kim HH, Ku JH, Kim HS
- KMID: 2471069
- Investig Clin Urol.
- 2020 Mar;61(2):136-145.
- doi: 10.4111/icu.2020.61.2.136
PURPOSE: To evaluate the impact of perioperative blood transfusion (PBT) on oncologic outcomes after surgery in patients with nonmetastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: This retrospective review included 2,329... -
- CITED
-
- Close
- SHARE
-
- Close
- Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
-
Woo CG, Yun SJ, Son SM, Lim YH, Lee OJ
- KMID: 2470924
- Yonsei Med J.
- 2020 Mar;61(3):262-266.
- doi: 10.3349/ymj.2020.61.3.262
The World Health Organization 2016 edition assigned anaplastic lymphoma kinase (ALK) rearrangement-associated renal cell carcinoma (ALK-RCC) as an emerging renal tumor entity. Identifying ALK-RCC is important because ALK inhibitors have... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
-
Choi SW, Lee JM, Kim DG, Noh MH
- KMID: 2471150
- Korean J Gastroenterol.
- 2020 Feb;75(2):103-107.
- doi: 10.4166/kjg.2020.75.2.103
A 64-year-old man was treated with sunitinib as a first-line therapy for metastatic renal cell carcinoma. He was given oral sunitinib in cycles of 50 mg once daily for 2... -
- CITED
-
- Close
- SHARE
-
- Close
- Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma
-
Hwang HS, Park YY, Shin SJ, Go H, Park JM, Yoon SY, Lee JL, Cho YM
- KMID: 2469348
- J Korean Med Sci.
- 2020 Feb;35(5):e31.
- doi: 10.3346/jkms.2020.35.e31
BACKGROUND: Mechanism and predictive biomarkers for tyrosine kinase inhibitor (TKI) resistance of advanced clear cell renal cell carcinoma (ccRCC) have not been fully evaluated. METHODS: We performed gene expression profiling on... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors
-
Choi J, Kim TJ, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Choi HY, Kang M, Seo SI
- KMID: 2470400
- Korean J Urol Oncol.
- 2019 Dec;17(3):150-159.
- doi: 10.22465/kjuo.2019.17.3.150
PURPOSE: To determine whether systemic inflammatory response (SIR), particularly platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR), has different prognostic role between patients with metastatic renal cell carcinoma (mRCC) receiving first-line... -
- CITED
-
- Close
- SHARE
-
- Close
- Comprehensive Molecular Characterization of Urological Malignancies: Literature Review of Landmark Studies
-
Suh J, Jeong CW
- KMID: 2470397
- Korean J Urol Oncol.
- 2019 Dec;17(3):125-135.
- doi: 10.22465/kjuo.2019.17.3.125
Owing to recent advancements in next-generation sequencing and bioinformatics, genetic data of urological malignancies exponentially studied and published. Application of precision medicine strategies for cancer diagnosis, management is just around... -
- CITED
-
- Close
- SHARE
-
- Close
- Initial Experience with Laparoscopic Mini-gastric Bypass in Korean Obese Patients
-
Lim CD, Kim SH, Kim YJ
- KMID: 2469715
- J Metab Bariatr Surg.
- 2019 Dec;8(2):43-49.
- doi: 10.17476/jmbs.2019.8.2.43
PURPOSE: To report our initial experience with laparoscopic mini-gastric bypass (LMGB) in Korean obese patients. MATERIALS AND METHODS: From July 2016 to February 2018, 14 male patients underwent LMGB for morbid... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical features and outcomes in kidney transplant recipients with renal cell carcinoma: a single-center study
-
Park KH, Yoon JA, Kim HS, Kim H, Park SK, Kim YH, Hong B, You D, Jeong IG, Baek CH
- KMID: 2469382
- Kidney Res Clin Pract.
- 2019 Dec;38(4):517-524.
- doi: 10.23876/j.krcp.19.078
BACKGROUND: Previous studies have recommended a 2- to 5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell carcinoma (RCC) and... -
- CITED
-
- Close
- SHARE
-
- Close
- Changing pattern and safety of pretransplant malignancy in kidney transplant recipients
-
Ban TH, Park WY, Jin K, Han S, Chung BH, Park SC, Choi BS, Park CW, Yun SS, Kim YS, Yang CW
- KMID: 2469381
- Kidney Res Clin Pract.
- 2019 Dec;38(4):509-516.
- doi: 10.23876/j.krcp.19.047
BACKGROUND: Cancer rates are increasing not only in the general population but also in patients with end-stage renal disease. We investigated the changing pattern of pretransplant malignancy in kidney transplant... -
- CITED
-
- Close
- SHARE
-
- Close
- Cutaneous metastatic renal cell carcinoma to the scalp
-
Yang HJ, Kang SY
- KMID: 2468779
- Arch Craniofac Surg.
- 2019 Dec;20(6):392-396.
- doi: 10.7181/acfs.2019.00206
Renal cell carcinoma (RCC) represents 2% to 3% of human cancers and is aggressive, with metastatic capability. The frequent metastatic sites are lung, bone, and liver. Reports of RCC metastatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases
-
Sayan M, Zoto Mustafayev T, Sahin B, Kefelioglu ESS, Wang SJ, Kurup V, Balmuk A, Gungor G, Ohri N, Weiner J, Ozyar E, Atalar B
- KMID: 2468735
- Radiat Oncol J.
- 2019 Dec;37(4):265-270.
- doi: 10.3857/roj.2019.00409
PURPOSE: Renal cell carcinoma (RCC) and melanoma have been considered ‘radioresistant’ due to the fact that they do not respond to conventionally fractionated radiation therapy. Stereotactic radiosurgery (SRS) provides high-dose... -
- CITED
-
- Close
- SHARE
-
- Close
- Lichen Planus Developed During the Treatment with Nivolumab in a Patient with Lung Cancer: A Case Report and Literature Review
-
Park E, Koo T, Jo M, Yoo J, Park J
- KMID: 2465922
- Korean J Dermatol.
- 2019 Nov;57(9):551-555.
Nivolumab is a fully-humanized IgG4 monoclonal antibody that competitively binds to the programmed cell death receptor-1 protein (an immune check-point molecule) present on activated T cells. Nivolumab is approved for... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidental Solid Renal Masses: Radiologic Assessment and Managements
-
Kim DW, Kim SH
- KMID: 2464904
- J Korean Soc Radiol.
- 2019 Nov;80(6):1010-1029.
- doi: 10.3348/jksr.2019.80.6.1010
The steady increase in imaging studies has led to the incidental discovery of many renal masses. Although most incidental solid renal masses are asymptomatic and small in size, they are... -
- CITED
-
- Close
- SHARE
-
- Close
- Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker
-
Kim KH, Lee HH, Yoon YE, Na JC, Kim KS, Han WK
- KMID: 2461053
- Investig Clin Urol.
- 2019 Nov;60(6):425-431.
- doi: 10.4111/icu.2019.60.6.425
PURPOSE: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). MATERIALS AND METHODS: Between... -
- CITED
-
- Close
- SHARE
-
- Close
- Neutrophil-to-Lymphocyte Ratio Predicts Pathological Renal Sinus Fat Invasion in Renal Cell Carcinomas of ≤7 cm with Presumed Renal Sinus Fat Invasion
-
Kim J, Park JS, Heo JE, Elghiaty A, Jang WS, Rha KH, Choi YD, Ham WS
- KMID: 2460218
- Yonsei Med J.
- 2019 Nov;60(11):1021-1027.
- doi: 10.3349/ymj.2019.60.11.1021
PURPOSE: Computed tomography (CT) is the most useful diagnostic modality for staging renal cell carcinoma (RCC). However, CT is limited in its ability to predict renal sinus fat invasion (SFI).... -
- CITED
-
- Close
- SHARE
-
- Close
- A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma
-
Shi S, Ye S, Wu X, Xu M, Zhuo R, Liao Q, Xi Y
- KMID: 2460217
- Yonsei Med J.
- 2019 Nov;60(11):1013-1020.
- doi: 10.3349/ymj.2019.60.11.1013
PURPOSE: Effective biomarkers and models are needed to improve the prognostic prospects of clear cell renal cell carcinoma (ccRCC). The purpose of this work was to identify DNA methylation biomarkers... -
- CITED
-
- Close
- SHARE
-
- Close
- Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
-
Lee JB, Park HS, Park S, Lee HJ, Kwon KA, Choi YJ, Kim YJ, Nam CM, Cho NH, Kang B, Chung HC, Rha SY
- KMID: 2460606
- Cancer Res Treat.
- 2019 Oct;51(4):1578-1588.
- doi: 10.4143/crt.2018.671
PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
-
Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG, Seo JY, Park I, Lee JL
- KMID: 2460603
- Cancer Res Treat.
- 2019 Oct;51(4):1549-1556.
- doi: 10.4143/crt.2019.086
PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results... -
- CITED
-
- Close
- SHARE
-
- Close
